Abstract
This poster presentation will identify the risk of metabolic syndrome at baseline in a community-based pragmatic clinical trial of youth with bipolar spectrum disorder who are treated with second-generation antipsychotic (SGA) drugs. In addition, it will highlight the challenges of treating these youth (ie, completion of recommended laboratories) within a pragmatic clinical trial design.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
